S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
Log in

NASDAQ:ASNDAscendis Pharma A/S Stock Price, Forecast & News

$142.43
-0.14 (-0.10 %)
(As of 08/14/2020 04:00 PM ET)
Add
Compare
Today's Range
$141.11
Now: $142.43
$142.97
50-Day Range
$134.29
MA: $143.76
$156.01
52-Week Range
$90.06
Now: $142.43
$158.93
Volume2,810 shs
Average Volume218,697 shs
Market Capitalization$7.53 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.9
Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia. It also has strategic collaborations with Sanofi to develop TransCon Peptides for the treatment of diabetes; and Genentech and Roche to develop TransCon anti-vascular endothelial growth factor (VEGF), a compound to support injection of anti-VEGF in ophthalmology. Ascendis Pharma A/S was founded in 2006 and is headquartered in Hellerup, Denmark.
Read More
Ascendis Pharma A/S logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.55 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ASND
CUSIPN/A
Phone45-7022-2244

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$14.98 million
Book Value$15.87 per share

Profitability

Net Income$-244,180,000.00
Net Margins-2,231.94%

Miscellaneous

Employees216
Market Cap$7.53 billion
Next Earnings Date8/27/2020 (Confirmed)
OptionableOptionable
$142.43
-0.14 (-0.10 %)
(As of 08/14/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ASND News and Ratings via Email

Sign-up to receive the latest news and ratings for ASND and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Ascendis Pharma A/S (NASDAQ:ASND) Frequently Asked Questions

How has Ascendis Pharma A/S's stock price been impacted by COVID-19 (Coronavirus)?

Ascendis Pharma A/S's stock was trading at $118.53 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ASND shares have increased by 20.2% and is now trading at $142.43.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Ascendis Pharma A/S?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ascendis Pharma A/S in the last year. There are currently 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Ascendis Pharma A/S
.

When is Ascendis Pharma A/S's next earnings date?

Ascendis Pharma A/S is scheduled to release its next quarterly earnings announcement on Thursday, August 27th 2020.
View our earnings forecast for Ascendis Pharma A/S
.

How were Ascendis Pharma A/S's earnings last quarter?

Ascendis Pharma A/S (NASDAQ:ASND) released its earnings results on Tuesday, May, 19th. The biotechnology company reported ($1.32) EPS for the quarter, beating the Zacks' consensus estimate of ($1.43) by $0.11. The biotechnology company had revenue of $2.45 million for the quarter, compared to the consensus estimate of $2.66 million. Ascendis Pharma A/S had a negative return on equity of 36.56% and a negative net margin of 2,231.94%.
View Ascendis Pharma A/S's earnings history
.

What price target have analysts set for ASND?

11 Wall Street analysts have issued 12 month target prices for Ascendis Pharma A/S's shares. Their forecasts range from $145.00 to $208.00. On average, they expect Ascendis Pharma A/S's stock price to reach $171.91 in the next year. This suggests a possible upside of 20.7% from the stock's current price.
View analysts' price targets for Ascendis Pharma A/S
.

Has Ascendis Pharma A/S been receiving favorable news coverage?

News coverage about ASND stock has been trending somewhat negative on Friday, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Ascendis Pharma A/S earned a coverage optimism score of -1.8 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future.
View the latest news about Ascendis Pharma A/S
.

Are investors shorting Ascendis Pharma A/S?

Ascendis Pharma A/S saw a increase in short interest during the month of January. As of January 15th, there was short interest totaling 2,430,000 shares, an increase of 12.5% from the December 31st total of 2,160,000 shares. Based on an average trading volume of 250,000 shares, the days-to-cover ratio is currently 9.7 days. Approximately 5.5% of the shares of the stock are sold short.
View Ascendis Pharma A/S's Short Interest
.

Who are some of Ascendis Pharma A/S's key competitors?

What other stocks do shareholders of Ascendis Pharma A/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ascendis Pharma A/S investors own include AbbVie (ABBV), Neurocrine Biosciences (NBIX), Alexion Pharmaceuticals (ALXN), Exelixis (EXEL), Gilead Sciences (GILD), GW Pharmaceuticals PLC- (GWPH), Incyte (INCY), NVIDIA (NVDA), ACADIA Pharmaceuticals (ACAD) and BioMarin Pharmaceutical (BMRN).

Who are Ascendis Pharma A/S's key executives?

Ascendis Pharma A/S's management team includes the following people:
  • Mr. Michael Wolff Jensen, Chairman, Sr. VP & Chief Legal Officer (Age 48)
  • Mr. Jan Møller Mikkelsen, Pres, CEO, Member of Exec. Board & Exec. Director (Age 59)
  • Mr. Scott T. Smith, CFO, Sr. VP & Member of Exec. Board (Age 45)
  • Mr. Peter Rasmussen, VP of Fin. & Principal Accounting Officer (Age 50)
  • Ms. Lotte Sønderbjerg, Chief Admin. Officer & Sr. VP (Age 58)

When did Ascendis Pharma A/S IPO?

(ASND) raised $85 million in an initial public offering on Wednesday, January 28th 2015. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. BofA Merrill Lynch and Leerink Partners served as the underwriters for the IPO and Wells Fargo Securities was co-manager.

What is Ascendis Pharma A/S's stock symbol?

Ascendis Pharma A/S trades on the NASDAQ under the ticker symbol "ASND."

Who are Ascendis Pharma A/S's major shareholders?

Ascendis Pharma A/S's stock is owned by a variety of institutional and retail investors. Top institutional investors include FMR LLC (9.08%), Victory Capital Management Inc. (0.75%), New York State Common Retirement Fund (0.48%), TimesSquare Capital Management LLC (0.43%), Candriam Luxembourg S.C.A. (0.40%) and Driehaus Capital Management LLC (0.35%).

Which institutional investors are selling Ascendis Pharma A/S stock?

ASND stock was sold by a variety of institutional investors in the last quarter, including Cormorant Asset Management LP, FIL Ltd, Artal Group S.A., Marshall Wace North America L.P., New York State Common Retirement Fund, Bank of America Corp DE, Tekla Capital Management LLC, and UBS Group AG.

Which institutional investors are buying Ascendis Pharma A/S stock?

ASND stock was purchased by a variety of institutional investors in the last quarter, including TimesSquare Capital Management LLC, Candriam Luxembourg S.C.A., Avidity Partners Management LP, California Public Employees Retirement System, FMR LLC, Athanor Capital LP, Envestnet Asset Management Inc., and Driehaus Capital Management LLC.

How do I buy shares of Ascendis Pharma A/S?

Shares of ASND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Ascendis Pharma A/S's stock price today?

One share of ASND stock can currently be purchased for approximately $142.43.

How big of a company is Ascendis Pharma A/S?

Ascendis Pharma A/S has a market capitalization of $7.53 billion and generates $14.98 million in revenue each year. The biotechnology company earns $-244,180,000.00 in net income (profit) each year or ($5.25) on an earnings per share basis. Ascendis Pharma A/S employs 216 workers across the globe.

What is Ascendis Pharma A/S's official website?

The official website for Ascendis Pharma A/S is www.ascendispharma.com.

How can I contact Ascendis Pharma A/S?

Ascendis Pharma A/S's mailing address is TUBORG BOULEVARD 12, HELLERUP G7, DK-2900. The biotechnology company can be reached via phone at 45-7022-2244 or via email at [email protected]

This page was last updated on 8/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.